Acm Global Central Laboratory
Acm Global Central Laboratory is recorded as a service provider in 87 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 87 trials · Latest update first
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants with Major Depressive Disorder (EMBRACE)
Sponsor Cybin IRL Limited
- Start (EU)
- Latest update
- Estimated end
Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)
Sponsor Aop Orphan Pharmaceuticals GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
A Global, Randomized, Open-label, Multicenter Phase 3 Trial Evaluating BJT-778 vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Sponsor Mirum Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)
Sponsor Alvotech Swiss AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, 2-Treatment Arm Study to Assess Comparative Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Intravenous AVT32-DRL_PB and Keytruda® as an Adjuvant Treatment in Participants with Stage IIB/C-III Melanoma Following Complete Resection
Sponsor Alvotech Swiss AG
- Start (EU)
- Latest update
- Estimated end
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1)
Sponsor Glaukos Corp.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer
Sponsor Acrivon Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
Sponsor AnaCardio AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)
Sponsor Ascentage Pharma Group Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
Sponsor Eyebiotech Limited
- Start (EU)
- Latest update
- Estimated end
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults with Major Depressive Disorder (MDD), with or without Anxious Distress
Sponsor Seaport Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
Sponsor Xenon Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs.
Sponsor Debiopharm International S.A.
- Start (EU)
- Latest update
- Estimated end
A phase 3, randomised, 2-arm, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of subcutaneous methotrexate versus placebo in moderate to severe atopic dermatitis
Sponsor Medac Gesellschaft fuer klinische Spezialprapaerate mbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
Sponsor River 3 Renal Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Of 96 screened patients, 53 screen failed.
- Twenty-six centers in six countries consented at least one participant, but only 17 centers enrolled at least one participant.
- Eligibility criteria were amended to lower the minimum eGFR from 45 to 30 mL/min/1.73 m² in both cohorts and the FSGS minimum UPCR from 3.5 to 1.5 g/g.
- Intended 24-hour urine collections were added at baseline and end of treatment because of high variability in first-morning-void UPCR measurements.
These findings describe the trial, not the service provider’s performance or responsibility.
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-stage Renal Disease Treated with Hemodialysis
Sponsor Amicus Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Sponsor Maplight Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Acm Global Central Laboratory?
The 2026-10-09 snapshot links Acm Global Central Laboratory to 87 distinct CTIS trials. Recorded services include Laboratory services, Storage, Clinical chemistry, Clinical haematology, Clinical chemistry, Clinical haematology, Serology / endocrinology, PK / PD, among 16 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Acm Global Central Laboratory?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Dermatology, Neurology, Psychiatry. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Acm Global Central Laboratory conducted?
The linked trials record locations in 25 countries, including Germany, Spain, Italy, Poland, France. These are trial locations, not confirmed office locations or countries where Acm Global Central Laboratory delivered services.
What can this page tell me about Acm Global Central Laboratory's trial experience?
Browse 87 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Acm Global Central Laboratory. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Acm Global Central Laboratory Limited